Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming ...

Pfizer shareholders held their Annual Meeting on April 23, 2026, where they re-elected the full slate of board nominees, including Chief Executive Albert Bourla and other incumbent directors, for ...

Pfizer Inc PFE shares are dipping on Tuesday. The company announced a series of settlement agreements that extend the effective U.S. patent life of Vyndamax, its treatment for transthyretin‑mediated ...

Pfizer said on Tuesday that it has reached settlement agreements with three generic manufacturers — Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd. — resolving patent-infringement lawsuits over ...

It's still time to pick up their shares on the dip.

Pfizer has reached legal settlements with three drug manufacturers related to alleged patent infringement for its Vyndamax drug. The biopharmaceutical company said Tuesday that it settled with Dexcel ...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.